Search Medical Condition
Please enter condition
Please choose location

Ariana, Tunisia Clinical Trials

A listing of Ariana, Tunisia clinical trials actively recruiting patients volunteers.

RESULTS

Found (27) clinical trials

Study to Compare the Efficacy of Pristinamycin (Pyostacine ) Versus Amoxicillin in the Treatment of Acute Community Acquired Pneumonia

The total study duration for each patient is 1 month with a treatment period of 7 to 9 days and a follow-up period of 21 to 23 days.

Phase

0.0 miles

Learn More »

A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.

Renal cell carcinoma (RCC) accounts for more than 200,000 new cases of cancer and over 100,000 cancer deaths annually in the World (Ferlay, et al., 2004). It is estimated that there were about 15,000 new cases of RCC in the region that excludes the Americas, European Union and Japan. Renal ...

Phase

0.0 miles

Learn More »

Allopurinol and Endothelial Function in Diabetic CAD Patients

This is a randomized trial assessing the impact of allopurinol on endothelial function in optimally treated diabetic patients with coronary artery disease. After initial screening, subjects were randomized to receive either optimal medical therapy (OMT) + allopurinol or OMT alone for 8 weeks. The dose of allopurinol was 300 mg ...

Phase N/A

0.0 miles

Learn More »

Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer

Pilot study evaluating the safety and efficacy of adding Bevacizumab to neoadjuvant chemotherapy in patients presenting non metastatic inflammatory breast cancer (IBC). Patients will receive 4 cycles of chemotherapy FEC100 associating Fluorouracil (500 mg/m2), Epirubicin (100 mg/m2), Cyclophosphamide (500 mg/m2) and Bevacizumab 15 mg/kg every at day 1 of ecah ...

Phase

4.19 miles

Learn More »

Study to Compare the Efficacy of Tocilizumab With or Without Glucocorticoid Discontinuation in Rheumatoid Arthritis Participants

This Phase IIIb/IV, two-arm, randomized, double-blind, placebo-controlled, parallel-group, international, multicenter trial compares the change in disease activity (as assessed by Disease Activity Score in 28 joints [DAS28] erythrocyte sedimentation rate [ESR]) from randomization to Week 24 post-randomization, in participants with stable low disease activity [LDA] (DAS28 ESR score less than ...

Phase

4.25 miles

Learn More »

Global Non-interventional Heart Failure Disease Registry

The clinical characteristics, initial presentation, management, and outcomes of patients hospitalized with new-onset (first diagnosis) heart failure (HF) or decompensation of chronic HF are poorly understood worldwide. REPORT-HF is a global, prospective, and observational HF disease registry designed to characterize patient trajectories longitudinally during and following an index hospitalization for ...

Phase N/A

4.25 miles

Learn More »

Study to Evaluate Treatment Compliance Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron Overload

This is a randomized, open-label, multicenter, two arm, phase II study to evaluate treatment compliance and change in serum ferritin of a deferasirox granule formulation and a deferasirox DT formulation in children and adolescents aged 2 and < 18 years at enrollment with any transfusion-dependent anemia requiring chelation therapy due ...

Phase

4.25 miles

Learn More »

Comparison of Thromboembolic Events Between Enoxa and Lovenox in Patients Undergoing Digestive Cancer

Comparative study with two arms versus ENOXA® LOVENOX®, randomized, prospective, single-center, with rater-blinded whose main objective is to compare the incidence of thromboembolic events (symptomatic and asymptomatic) between the two arms of the study, in patients undergoing digestive cancer and receiving thromboprophylaxis based SODIUM enoxaparin.

Phase

4.25 miles

Learn More »

EDS in Ataxia Telangiectasia Patients

All patients who complete the assessments as designed over the initial 6 months of the trial will be eligible to continue in an additional 6-month, double-blind, placebo-controlled extension designed to collect information on the long-term safety and efficacy of the trial treatments. Upon completion of all screening assessments for eligibility ...

Phase

4.25 miles

Learn More »

Pharmacokinetic Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen Deficiency

The present study is designed as a prospective, open-label, multicentre, phase I/III study investigating the 14 day single-dose pharmacokinetic properties, efficacy and safety of BT524 following intravenous administration in the treatment or prophylaxis of bleeding in patients with congenital afibrinogenemia or severe congenital hypofibrinogenemia.

Phase

4.25 miles

Learn More »